# KT-621 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kt-621

> The next catalyst for KT-621, sponsored by Kymera Therapeutics, Inc. (KYMR), is its trial start, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for KT-621?

The next catalyst for KT-621, sponsored by Kymera Therapeutics, Inc. (KYMR), is its trial start, mid-2027. SEC Form 8-K: "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026." [Calendar and source filings](https://sec-api.dev/pdufa/kt-621)

Source: SEC Form 8-K, accession 0001193125-26-281817, https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/kt-621#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | KT-621 |
| Codes | KT-621 |
| Sponsor | Kymera Therapeutics, Inc. (KYMR) https://sec-api.dev/companies/kymr/catalysts |
| Indications | moderate to severe eosinophilic asthma, with topline data, [moderate to severe ad](https://sec-api.dev/indications/moderate-to-severe-ad), [asthma](https://sec-api.dev/indications/asthma), [Eosinophilic Asthma](https://sec-api.dev/indications/eosinophilic-asthma), [Atopic Dermatitis](https://sec-api.dev/indications/atopic-dermatitis), [Asthma (Diagnosis)](https://sec-api.dev/indications/asthma-diagnosis) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-27, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-037588): "In October 2024, Kymera initiated a Phase 1 clinical trial with KT-621 in healthy volunteers." https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874dex991.htm

### 1H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-01-14, last confirmed 2025-01-14.
- SEC Form 8-K (accession 0001193125-25-006124): "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives for clinical development of its clinical and preclinical pipeline including the therapeutic potential, clinical benefits and safety thereof, the Phase 1 data readout of KT-621 in the first half of 2025 and plans to initiate a Phase 1b trial in atopic dermatitis (AD) patients in the second quarter of" https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-01-14, last confirmed 2025-01-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-006124): "Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in" https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233dex991.htm
- SEC Form 8-K (accession 0001193125-25-006124): "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives for clinical development of its clinical and preclinical pipeline including the therapeutic potential, clinical benefits and safety thereof, the Phase 1 data readout of KT-621 in the first half of 2025 and plans to initiate a Phase 1b trial in atopic dermatitis (AD) patients in the second quarter of" https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm

### Nov 2025: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-01-13, last confirmed 2026-01-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-011104): "Dosing commenced in November 2025 for the KT-621 BROADEN2 Phase 2b trial, a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 200 patients with moderate to severe AD over 16 weeks." https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/d78447dex991.htm

### Jan 2026: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-02-26, last confirmed 2026-04-30.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-193957): "In January 2026, the Company commenced dosing in the BREADTH Phase 2b clinical trial, a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 264 adult patients with moderate to severe eosinophilic asthma over 12 weeks." https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073386): "In January 2026, the Company commenced dosing in the BREADTH Phase 2b clinical trial, a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 264 adult patients with moderate to severe eosinophilic asthma over 12 weeks." https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-ex99_1.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: asthma.
- First seen 2025-01-14, last confirmed 2025-12-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-310670): "our expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of the Phase 2b study of KT-621 in patients with asthma in the first quarter of 2026, the effect of initial parallel development of" https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-037588): "Phase 1b trial of KT-621 in AD patients in the second quarter of 2025, with data expected to be reported in the fourth quarter of 2025, the initiation of Phase 2b studies of" https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874dex991.htm
- SEC Form 8-K (accession 0001193125-25-006124): "The Company also announced plans to advance KT-621, the Company's investigational oral degrader of STAT6, into a Phase 1b clinical trial in atopic dermatitis (AD) patients in the second quarter of 2025 with data expected in the fourth quarter of 2025 and plans to initiate parallel Phase 2b clinical trials of KT-621 in AD and asthma in late 2025 and early 2026, respectively." https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-006124): "We are rapidly progressing the development of our first-in-industry oral STAT6 degrader, KT-621, and will have Phase 1 healthy volunteer data, Phase 1b atopic dermatitis data, as well as initiate the first Phase 2b study, all in 2025." https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233dex991.htm
- SEC Form 8-K (accession 0001193125-25-006124): "2025 with data in the fourth quarter of 2025 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively." https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-006124): "4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively" https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233dex991.htm

### late 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: moderate to severe AD.
- First seen 2026-06-25, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "The Company plans to report topline data by year-end 2026." https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-333834): "The earlier than expected completion of enrollment enabled the Company to accelerate its expected topline data readout by six months to year-end 2026, earlier than prior guidance to share data by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-281817): "Enrollment was completed in advance of prior expectations, and the Company expects this development to accelerate the timing of its anticipated topline data readout to year-end 2026, representing a potential advancement of six months relative to its prior expectation of releasing the readout in mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-281817): "The earlier than expected completion of enrollment enables Kymera to accelerate its expected topline data readout by six months to year-end 2026, earlier than prior guidance to share data by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-333834): "The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options."" https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-281817): ""With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent readouts, and NDA filing."" https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026." https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-281817): "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-281817): "Phase 2b studies in AD and asthma patients on acceleration of late parallel development and dose selection across multiple indications, Phase 2b data readout of KT-621 in patients with moderate to severe AD expected by year end 2026." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555dex991.htm

### mid-2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-06-25, last confirmed 2026-10-29.
- SEC Form 8-K (accession 0001193125-26-281817): "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027."" https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-333834): "Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-281817): "Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07217015

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Atopic Dermatitis.
- First seen 2025-11-04, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07217015
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be reported in late 2027" https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436965): "Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-263540): "The KT-621 BROADEN2 Phase 2b trial in AD has been initiated with topline data expected by mid-2027." https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-ex99_1.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Eosinophilic Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07323654

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Eosinophilic Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07323654

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Asthma (Diagnosis).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07677059 (A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07677059

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Asthma (Diagnosis).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07677059 (A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07677059

## Same indication

- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)
- [ATI-045](https://sec-api.dev/pdufa/ati-045) (ACRS)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820) (PFE)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3) (ARQT)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [Soquelitinib](https://sec-api.dev/pdufa/soquelitinib) (CRVS)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kt-621.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KT-621 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kt-621

```bibtex
@misc{secapidev_pdufa_kt_621_20261116,
  title        = {KT-621 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kt-621}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kt_621_20261116","title":"KT-621 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kt-621","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
